Loading stock data…
Acrivon Therapeutics (ACRV)
$2.10-0.03 (-1.41%)
After Hours$2.18+0.08 (+3.81%)· Last close Sep 8
Acrivon Therapeutics, Inc., a clinical-stage biopharmaceutical company, discovers and develops oncology medicines for patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its generative phosphoproteomics platform.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Acrivon Therapeutics, Inc. in the Healthcare sector is trading at $2.10 with a market capitalization of $64M. Wall Street consensus targets $11.50 (6 analysts), implying a +447.6% move over the next 12 months. The stock is currently 41% below its 52-week high of $3.56, remaining 13.5% above its 200-day moving average. On fundamentals, Piotroski 2/9 flags weak fundamentals, Altman Z in the distress zone. The Whystock Score of 50/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +447.6% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$19.90M↑ | -$20.12M↓ | -$19.69M↑ | -$22.65M↓ | -$21.66M |
| Net Income | -$19.04M↓ | -$18.98M↓ | -$18.23M↑ | -$21.01M↓ | -$19.68M |
Peer Comparison
JNJUNHPFE
Fundamentals
Acrivon Therapeutics, Inc., a clinical-stage biopharmaceutical company, discovers and develops oncology medicines for patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its generative phosphoproteomics platform...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$64.25M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-80.90%
Volume
Today's trading volume
126,371
Recent News
Acrivon Therapeutics, Inc. (ACRV) Just Flashed Golden Cross Signal: Do You Buy?
When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?
Here's Why Acrivon Therapeutics, Inc. (ACRV) is a Great Momentum Stock to Buy
Does Acrivon Therapeutics, Inc. (ACRV) have what it takes to be a top stock pick for momentum investors? Let's find out.
Acrivon Therapeutics, Inc. (ACRV) Upgraded to Buy: Here's Why
Acrivon Therapeutics, Inc. (ACRV) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Acrivon Therapeutics Conference Highlights ACR-368 Phase 2B Data, 52% ORR in Serous Endometrial Cancer
Acrivon Therapeutics (NASDAQ:ACRV) hosted a webcast featuring a key opinion leader (KOL) panel focused on the company’s ongoing ACR-368 registrational-intent Phase 2B study in endometrial cancer, with particular attention on results in serous endometrial cancer. The panel discussion followed a late-
Penny Stocks To Watch In January 2026
As the U.S. markets grapple with recent declines and rising Treasury yields, investors are keenly observing potential opportunities in various sectors. Penny stocks, while often seen as relics of past market trends, continue to offer intriguing possibilities for those willing to explore smaller or newer companies at accessible price points. By focusing on solid financials and growth potential, these stocks can present unique opportunities for investors looking to tap into under-the-radar...